Dr Reddy's launches insomnia treatment drug in US market

had US sales of approximately $887 mn for the most recent 12 months ending in January 2014

Hyderabad-based Pharmaceutical major Dr Reddy's Laboratories on Wednesday stated that it has launched Eszopiclone tablets (C-IV) 1 mg, 2 mg and 3 mg in the US market, following the approval by the United States Food & Drug Administration (USFDA).

Eszopiclone, a therapeutic equivalent generic version of Lunesta (eszopiclone) tablets, is a sedative drug used for treatment of insomnia.

The Lunesta (eszopiclone) tablets C-IV brand and generic combined had US sales of approximately $887 million for the most recent 12 months ending in January 2014, according to IMS Health.

Dr Reddy's tablets of 1 mg is available in bottle counts of 30, while 2 mg and 3 mg are available in bottle counts of 100.

The company scrip was trading on BSE at Rs 2552.60, down 0.96 per cent over the previous close of Rs 2,577.45.